Related Articles by Review for PMID: 21422473

Year	Number of Results
2011	3
2012	11
2013	22
2014	9
2015	5
2016	4
2017	1
2019	2
2020	4
2021	6
2022	11
2023	11
2024	3

1

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Herman SE, et al. Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21. Blood. 2011. PMID: 21422473 Free PMC article.

2

Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.

Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M. Gozzetti A, et al. Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342. Anticancer Agents Med Chem. 2017. PMID: 27697038 Review.

3

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV. Danilov AV. Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Clin Ther. 2013. PMID: 24054703 Free PMC article. Review.

4

Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Smith CIE, Burger JA. Smith CIE, et al. Front Immunol. 2021 Jun 10;12:689472. doi: 10.3389/fimmu.2021.689472. eCollection 2021. Front Immunol. 2021. PMID: 34177947 Free PMC article. Review.

5

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Wiestner A. Wiestner A. Hematology Am Soc Hematol Educ Program. 2012;2012:88-96. doi: 10.1182/asheducation-2012.1.88. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233565 Review.

6

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.

Jain N, O'Brien S. Jain N, et al. Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006. Hematol Oncol Clin North Am. 2013. PMID: 23915749 Free PMC article. Review.

7

Ibrutinib: a paradigm shift in management of CLL.

Badar T, Burger JA, Wierda WG, O'Brien S. Badar T, et al. Expert Rev Hematol. 2014 Dec;7(6):705-17. doi: 10.1586/17474086.2014.977862. Expert Rev Hematol. 2014. PMID: 25387837 Free PMC article. Review.

8

Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.

Burger JA. Burger JA. Curr Opin Oncol. 2012 Nov;24(6):643-9. doi: 10.1097/CCO.0b013e3283589950. Curr Opin Oncol. 2012. PMID: 22960555 Review.

9

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Wiestner A. Wiestner A. Haematologica. 2015 Dec;100(12):1495-507. doi: 10.3324/haematol.2014.119123. Haematologica. 2015. PMID: 26628631 Free PMC article. Review.

10

BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.

Robak T, Robak P. Robak T, et al. Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25. Int Rev Immunol. 2013. PMID: 23617253 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83 results

Results by year